Clin Mol Hepatol > Volume 26(4); 2020 > Article
Oh and Lee: Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma
Sarcopenia is defined as the progressive and generalized loss of skeletal muscle mass, strength, and function [1,2]. It primarily occurs in relation to the normal aging process, but is also described with various medical illnesses, including liver cirrhosis (LC) and hepatocellular carcinoma (HCC) [1-3]. Sarcopenia in patients with LC is classified as secondary sarcopenia associated with disease (cirrhosis), low physical activity (e.g., disuse), and/or malnutrition (e.g., protein deficiency) [1,4]. Sarcopenia is a common feature of malnutrition among patients with LC or HCC, and has been widely recognized as an independent predictor of clinical outcomes in patients with LC and as a prognostic factor in patients with HCC [1,5-8].
In the current issue of Clinical and Molecular Hepatology, Choi and colleagues [9] presented a study demonstrating serum levels of three myokines (myostatin, follistatin, and interleukin-6 [IL-6]) and their correlation with sarcopenia and survival in HCC patients. This article is timely, and it also covers critical topics on sarcopenia and its impact on survival in patients with HCC. The strength of this study relies on the novel approach used to identify the predictive biomarker of sarcopenia and survival in patients with HCC by using serum myokine levels. The authors evaluated sarcopenia using the psoas muscle index (PMI) measured at the third lumbar level on computed tomography, and reported an overall sarcopenia prevalence of 56.4% in 238 ethnically homogenous South Korean patients with HCC [9].
Myokines are cytokines produced and secreted by muscle fibers, and they are known to exert autocrine or paracrine effect [10]. Myokines take part in immune responses, and have anti-inflammatory or immunoprotective effects [11]. Therefore, sarcopenia may facilitate the proinflammatory state of cirrhosis and further potentiate the progression of liver fibrosis and development of HCC [1,12]. In the present study, Choi et al. [9] reported that the serum levels of the three myokines were differently correlated with PMI in patients with HCC. The median levels of the three myokines in the patients with HCC were all significantly higher than those in healthy controls, and the serum follistatin level was an independent factor of poor survival in the patients with HCC [9]. In a recent Japanese study, Nishikawa et al. [13] found that higher serum myostatin levels were correlated with sarcopenia, hyperammonemia, and impaired protein synthesis, as reflected by the lower serum albumin levels in patients with LC. They suggested the use of serum myostatin level as a potential biomarker, and demonstrated the association of high myostatin levels with both sarcopenia and worse survival in patients with LC [13]. In contrast, the report by Choi et al. [9] indicated an inverse correlation between serum myostatin level and sarcopenia in patients with HCC. In their study, serum myostatin levels showed a positive correlation with PMI (ρ=0.356, P<0.001), and the overall survival rate was not significantly different between the high and low myostatin groups [9]. In contrast, the serum IL-6 level showed a weak negative correlation with PMI (ρ=-0.174, P=0.009), and serum follistatin level approached statistical significance towards a negative correlation (ρ=-0.124, P=0.055). Moreover, HCC patients with high levels of follistatin or IL-6 had a significantly lower 5-year overall survival rate [9].
Myostatin is a cytokine belonging to the transforming growth factor beta (TGF-β) family. As a negative regulator of muscle protein synthesis, it strongly suppresses skeletal muscle growth [1,14]. Hyperammonemia, as a possible mediator in the liver-muscle axis, and the related upregulation of myostatin are regarded as mechanisms of the impaired protein synthesis and increased autophagy, which is linked to the development of sarcopenia in LC patients [13,15]. Protein synthesis is biochemically upregulated by the mammalian target of rapamycin complex 1 (mTORC1), which is counterbalanced by an inhibitor, myostatin (Fig. 1) [1,16]. Increased serum myostatin expression level in patients with LC is believed to be associated with anabolic resistance, and can represent an adverse predictor of patients with LC [13,17]. In view of the results from the study by Nishikawa et al. [13], serum myostatin levels appeared to be closely related to the hepatic functional reserve. In their study, serum myostatin level was significantly correlated with serum ammonia level, and this result can support the hypothesis that skeletal muscle mass depletion can occur via impaired ammonia detoxification and its related higher myostatin expression [13,18]. However, in the study by Choi et al. [9], serum myostatin level showed a positive correlation with PMI and had no significant association with the overall survival in South Korean patients with HCC. This discrepancy may have resulted from the difference in the study population, LC vs. HCC patients. Although the exact mechanism is yet to be defined, the authors suspect that the development of HCC might change the regulatory pathway of myostatin metabolism, which leads to decreased bioavailability of myostatin [9]. In addition, in the study of patients with LC by Nishikawa et al. [13], serum myostatin level did not influence the survival of patients with hepatitis C virus (HCV)-related LC. However, in the subjects with non-viral hepatitis-related LC, the influence of serum myostatin level on survival was prominent [13]. This difference might be attributed to the different causes of death for the subjects with HCV-related and non-virus-related LC. Most of the patients with non-virus-related LC died from liver failure, which was in line with the association between serum myostatin level and liver functional reserve. However, the patients with HCV-related LC or HCC tended to die from tumor progression rather than from liver failure, as compared to the patients with non-virus-related LC [13]. Choi et al. [9] also revealed that serum follistatin and IL-6 levels remarkably increased according to tumor progression by Barcelona Clinic Liver Cancer (BCLC) or tumor, nodes, metastasis (TNM) tumor stage in patients with HCC. Meanwhile, serum myostatin level did not correlate well with the TNM or BCLC tumor stage, but correlated well with the Child-Pugh class or liver functional reserve [9].
Myostatin antagonists, such as follistatin, and mTORC1 activators have the potential to reverse sarcopenia in cirrhosis [13]. However, the influence of such agents on clinical outcomes has not been fully studied yet, and additional investigations are needed [14,19]. Follistatin is a secreted glycoprotein and a strong inhibitor of the TGF-β superfamily, which includes myostatin and activin [9,20]. Thus, follistatin inhibits myostatin-mediated sarcopenia and has been proven in animal studies to improve skeletal muscle mass, but it should not yet be used for patients with LC or HCC-related sarcopenia [1]. Nevertheless, the follistatin expression level was increased in approximately 60% of tumor tissues and also in human liver cancer [20]. This was consistent with the results reported by Choi et al. [9], where the follistatin level increased with the tumor stage and size, suggesting an oncogenic role of follistatin overexpression in hepatocarcinogenesis. Future studies are needed to address and clarify the roles of these myokines (e.g., myostatin, activin, and follistatin) during liver fibrosis and carcinogenesis in LC and HCC experimental models. In addition, several novel studies using antioxidants, mitochondrial protective agents, and new myostatin inhibitors for sarcopenic patients with LC or HCC are now being recognized [1]. Further studies are required to confirm whether antisarcopenia treatment prolongs the survival and reverses the molecular abnormalities underlying sarcopenia in patients with LC and HCC [3].


Authors’ contributions
S Oh: manuscript writing and critical revision; J Lee: critical revision and supervision
Conflicts of Interest
The authors have no conflicts of interests to disclose.

Figure 1.
The signaling pathways involved in the control of muscle protein synthesis and breakdown. Green boxes contain promoters of muscle protein synthesis or hypertrophy. Purple boxes contain promoters of muscle protein breakdown or atrophy. Green arrows: activating pathways; red arrows: inhibitory pathways. Asterisks (*) indicate potential therapeutic targets for reversing sarcopenia in cirrhosis. Modified from Anand [1]. IGF-1, insulin-like growth factor 1; Smad2/3, SMAD family member 2/3; AKT/PKB, serine/threonine-specific protein kinase B; FOXO, forkhead transcription factors of the O class; TNF-α, tumor necrosis factor-α; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor kappa B; p70S6K, ribosomal protein S6 kinase B1; MAFbx, muscle atrophy F-box; MuRF1, muscle ring finger 1.



Barcelona Clinic Liver Cancer
hepatocellular carcinoma
hepatitis C virus
liver cirrhosis
mammalian target of rapamycin complex 1
psoas muscle index
transforming growth factor beta
tumor, nodes, metastasis


1. Anand AC. Nutrition and muscle in cirrhosis. J Clin Exp Hepatol 2017;7:340-357.
crossref pmid pmc
2. Bosy-Westphal A, Müller MJ. Identification of skeletal muscle mass depletion across age and BMI groups in health and disease--there is need for a unified definition. Int J Obes (Lond) 2015;39:379-386.
crossref pmid pdf
3. Ha Y, Kim D, Han S, Chon YE, Lee YB, Kim MN, et al. Sarcopenia predicts prognosis in patients with newly diagnosed hepatocellular carcinoma, independent of tumor stage and liver function. Cancer Res Treat 2018;50:843-851.
crossref pmid pmc pdf
4. Romiti A, Merli M, Martorano M, Parrilli G, Martino F, Riggio O, et al. Malabsorption and nutritional abnormalities in patients with liver cirrhosis. Ital J Gastroenterol 1990;22:118-123.
5. Voron T, Tselikas L, Pietrasz D, Pigneur F, Laurent A, Compagnon P, et al. Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma. Ann Surg 2015;261:1173-1183.
crossref pmid
6. Antonelli G, Gigante E, Iavarone M, Begini P, Sangiovanni A, Iannicelli E, et al. Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. United European Gastroenterol J 2018;6:1039-1048.
crossref pmid pmc
7. Begini P, Gigante E, Antonelli G, Carbonetti F, Iannicelli E, Anania G, et al. Sarcopenia predicts reduced survival in patients with hepatocellular carcinoma at first diagnosis. Ann Hepatol 2017;16:107-114.
crossref pmid
8. Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, et al. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. Oncol Lett 2017;14:1637-1647.
crossref pmid pmc
9. Choi K, Jang HY, Ahn JM, Hwang SH, Chung JW, Choi YS, et al. The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma. Clin Mol Hepatol 2020;26:492-505.
crossref pmid pmc pdf
10. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012;8:457-465.
crossref pmid pdf
11. Duggal NA, Niemiro G, Harridge SDR, Simpson RJ, Lord JM. Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity? Nat Rev Immunol 2019;19:563-572.
crossref pdf
12. Hung CH, Wang JH, Hu TH, Chen CH, Chang KC, Yen YH, et al. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol 2010;16:2265-2271.
crossref pmid pmc
13. Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, et al. Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis. J Cachexia Sarcopenia Muscle 2017;8:915-925.
crossref pmid pmc
14. Elkina Y, von Haehling S, Anker SD, Springer J. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle 2011;2:143-151.
crossref pmid pmc
15. Merli M, Giusto M, Molfino A, Bonetto A, Rossi M, Ginanni Corradini S, et al. MuRF-1 and p-GSK3β expression in muscle atrophy of cirrhosis. Liver Int 2013;33:714-721.
crossref pmid
16. Egerman MA, Glass DJ. Signaling pathways controlling skeletal muscle mass. Crit Rev Biochem Mol Biol 2014;49:59-68.
crossref pmid
17. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, Sinha-Hikim I, Ma K, Ezzat S, et al. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci U S A 1998;95:14938-14943.
crossref pmid pmc
18. Hakvoort TB, He Y, Kulik W, Vermeulen JL, Duijst S, Ruijter JM, et al. Pivotal role of glutamine synthetase in ammonia detoxification. Hepatology 2017;65:281-293.
crossref pmid
19. Rinnov AR, Plomgaard P, Pedersen BK, Gluud LL. Impaired follistatin secretion in cirrhosis. J Clin Endocrinol Metab 2016;101:3395-3400.
crossref pmid pdf
20. Deli A, Kreidl E, Santifaller S, Trotter B, Seir K, Berger W, et al. Activins and activin antagonists in hepatocellular carcinoma. World J Gastroenterol 2008;14:1699-1709.
crossref pmid pmc

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail:
Copyright © The Korean Association for the Study of the Liver.         
TODAY : 1748
TOTAL : 1792554
Close layer